title: [Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
abstract: We report 2 cases of metastatic rectal cancer patients who received chemotherapy with FOLFOXIRI plus bevacizumab(Bev). Case 1: A 54-year-old woman diagnosed with advanced rectal cancer with synchronous liver metastasis underwent a laparoscopic low anterior resection. After the operation, she received FOLFOXIRI plus Bev treatment, and experienced Grade 4 adverse events, including dyspnea and ventricular fibrillation(Vf). After chemotherapy, no other metastasis was detected except a liver metastasis, and partial resection of the liver was performed. Histopathological evaluation revealed that the effect of the chemotherapy was Grade 1a. After liver resection, FOLFOXIRI plus Bev was administered, and a recurrence of the rectal cancer was not detected. Case 2: A 44-year-old woman was diagnosed with advanced rectal cancer with synchronous liver metastasis, distant lymph nodes metastasis, and vaginal invasion. First a colostomy was performed and FOLFOXIRI plus Bev treatment was administered. Grade 3 adverse events, including tremor, neuralgia, and anemia occurred, and chemotherapy was stopped for 3 months. Her adverse events were not under control when progression of the disease was detected, and her treatment was changed to another chemotherapy regimen.
authors.affiliation: Dept. of Surgery, Fuchu Hospital.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Nishii
authors.forename: Yasutake
authors.initials: Y
authors.lastname: Uchima
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Yamakoshi
authors.forename: En
authors.initials: E
authors.lastname: Wang
authors.forename: Daisuke
authors.initials: D
authors.lastname: Nagashima
authors.forename: Toshiki
authors.initials: T
authors.lastname: Hirakawa
authors.forename: Naoki
authors.initials: N
authors.lastname: Aomatsu
authors.forename: Takehiko
authors.initials: T
authors.lastname: Iwauchi
authors.forename: Junya
authors.initials: J
authors.lastname: Morimoto
authors.forename: Kazunori
authors.initials: K
authors.lastname: Nakazawa
authors.forename: Seika
authors.initials: S
authors.lastname: Tei
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takeuchi
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin